Colorectal

Colon cancer and rectum cancer are the second leading causes of cancer death in women and men combined. However, caught early enough, colon and rectal cancers can be prevented, treated, or cured.

Fewer than half of people found to have colorectal cancer are diagnosed at an early stage when treatment is most effective. This means that many people are living with a serious risk that they are not aware of. Screening offers greater peace of mind.

InSure^® ONE™  is a fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in fecal samples, which may be an indication of lower gastrointestinal bleeding associated with disorders such as diverticulitis, ulcerative colitis, polyps, colorectal cancers, or large adenomas that bleed.

The Hereditary Colorectal Cancer Panel includes 20 genes associated primarily with hereditary gastrointestinal cancers and possibly other cancers. This can include, but is not limited to, cancers of the colon, endometrium, stomach, urinary tract, ovary, pancreas, prostate, and rectum. Individuals with a positive result (pathogenic or likely pathogenic variant detected) have an increased risk for developing certain cancers compared to the general population.

The AmeriPath^® national network of board-certified pathologists provides comprehensive gastrointestinal (GI) pathology services utilizing state-of-the-art technologies including immunohistochemistry and molecular diagnostics.

Our nationally recognized GI pathology and liver disease expertise, combined with the delivery of world-class GI services in your community, helps ensure you receive clear and decisive diagnostic, prognostic, and therapeutic information promptly and in a cost-effective manner.

LiquidSEQ™ is a liquid biopsy for treatment selection. It provides a comprehensive molecular profile—including 523 genes associated with a broad spectrum of solid tumor cancers—that assesses the DNA only for single nucleotide variants (SNVs), copy number variants (CNVs), and fusions along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if the clinician desires a comprehensive analysis of a patient’s genetic profile from the patient’s blood in the event tissue is not available or is insufficient. This panel contains clinically actionable genes as well as emerging genes.

Precision medicine is an emerging approach for disease prevention and treatment that takes individual variability into account. This next-generation sequencing (NGS) panel, along with the computational resources and tools that process and analyze the data, allows the characterization of individual patients and tumor types. Guidelines exist for using results from many of these genes for selection of FDA-approved therapies.

Solid TumorSEQ™ provides a comprehensive molecular profile from biopsy tissue, including 523 genes associated with a broad spectrum of solid tumor cancers, and assesses the DNA and RNA for SNVs, CNVs, fusions, and splice variants along with genomic signatures, microsatellite instability (MSI), and tumor mutation burden (TMB). This panel would be used if a clinician desires a comprehensive analysis of a patient’s genetic profile from tumor tissue. This panel contains clinically actionable genes as well as emerging genes chosen based on alignment to guidelines, drug labels and clinical trials across multiple solid tumor types.

DPYD genotype testing supports you and your patients by contributing to patient safety initiatives, enhancing cost control, and delivering more optimal patient outcomes.

• Helping reduce severe and avoidable adverse events to Fluorouracil (5-FU)–based chemotherapy regimens
• Offering a simple, 1-time, targeted germline test with a person’s entire life cycle regardless of cancer type or staging
• Potentially reducing downstream costs associated with hospitalizations, ICU stays, and treatment delays
• Helping support your precision oncology initiatives through pharmacogenomics

Genetics can play a significant role in the selection of certain medications. For instance, individuals may metabolize medications too quickly or too slowly. This test analyzes genes of known pharmacogenomic value, allowing clinicians to gain valuable insight into an individual’s response to, and adverse effects from, medications with known gene-drug interactions.

Haystack MRD^®

Sensitivity matters when looking for the smallest evidence of disease, such as residual disease after surgery or response to adjuvant chemotherapy. Haystack MRD^® minimizes false negatives by detecting ultralow levels of ctDNA, providing confidence in therapeutic decisions.¹